摘要
目的观察老年结直肠癌患者术后采用XELOX方案辅助化疗的耐受性,以作为临床选择和调整化疗方案的参考。方法选取2014年7月至2020年6月我院收治的符合辅助治疗标准的结直肠癌患者作为研究对象,分为非老年组(<60岁)和老年组([60岁,75岁]),均接受希罗达联合奥沙利铂(XELOX)方案化疗,记录两组患者化疗通过情况、毒副反应情况及治疗前、后生命质量评测表(FACT-G)。结果在治疗后两组患者FACT-G评分均低于治疗前差异,具有统计学意义(P<0.05)。结论老年结直肠癌患者术后采用XELOX方案辅助化疗时,通过情况、毒副反应与非老年组未存在较大差异。因此,XELOX方案对于老年结直肠癌患者来说,不需要降低治疗强度的情况下,不明显增加毒性。
Objective To observe the tolerance of elderly patients with colorectal cancer treated with XELOX adjuvant chemotherapy after operation,as a reference for clinical selection and adjustment of chemotherapy.Methods From July 2014 to June 2020,colorectal cancer patients who met the criteria of adjuvant treatment in our hospital were divided into non elderly group(<60 years old)and elderly group([60 years old,75 years old]).All patients were treated with xeloda combined with oxaliplatin(XELOX)regimen chemotherapy,and their chemotherapy pass,toxicity and side effects,and life quality evaluation table(f)before and after treatment were recorded ACT-G).Results After treatment,the FACT-G scores of the two groups were lower than that before treatment,with statistical significance(P<0.05).Conclusion There is no significant difference between the elderly colorectal cancer patients and the non elderly group in terms of pass and side effects.Therefore,XELOX regimen for elderly colorectal cancer patients does not need to reduce the intensity of treatment,and does not significantly increase toxicity.
作者
陈焕新
吴佳悦
徐瑞芳
CHEN Huan-xin;WU Jia-yue;XU Rui-fang(Pengpai Memorial Hospital,Haifeng County,Shanwei,Guangdong 516400;People’s Hospital of Haifeng County,Shanwei,Guangdong 516400)
出处
《智慧健康》
2020年第31期86-87,90,共3页
Smart Healthcare
基金
2018年汕尾市科技计划(社会发展领域)项目(2018C003)
关键词
老年结直肠癌
术后XELOX方案
辅助化疗
耐受性
Elderly colorectal cancer
Postoperative XELOX regimen
Adjuvant chemotherapy
Tolerance
